Conditions A–Z

Topical CBD has emerging acne data, including Phase 2 development, but evidence remains formulation-specific and not yet standard care.

CBD is under active investigation in adolescent/adult focal-onset seizures, but efficacy is not established and there is no licensed indication.

CBD has the strongest evidence and is licensed for LGS, Dravet syndrome and TSC-associated seizures from age 2+, including patients who continue into adulthood.

THC analogue has strongest evidence

UK burden: Over 111,800 people living with HIV in the UK

Small topical studies support a CBD-containing formulation signal; evidence is product-specific and should not be generalised to oral CBD.

CBD-enriched has weak signal; specialist supervision essential

UK burden: At least 700,000 to 1,000,000 autistic people in the UK

Evidence signal exists; mixed Phase 3 results

UK burden: Cancer pain affects 30% to 50% of patients during treatment, up to 70% in advanced disease

THC analogue has strongest evidence

UK burden: Approximately 390,000 new cancer diagnoses per year in the UK; up to 80% of patients receiving emetogenic chemotherapy experience CINV

Evidence signal exists; UK guidance caution

UK burden: 7% to 8% of UK adults have chronic pain with neuropathic characteristics (approximately 3.4 to 4.7 million people)

Topical cannabinoid formulations show an emerging antipruritic signal, but evidence is small, heterogeneous and formulation-specific.

CBD has strongest evidence; licensed in indication

UK burden: Around 2,000 people living with Dravet syndrome in the UK

CBD is being investigated for endometriosis-associated pain, but current evidence is mixed and includes a negative randomized trial.

UK burden: Around 1.5 million people affected by endometriosis in the UK

CBD has emerging signal; chronic efficacy not established

UK burden: England adult GAD prevalence: 7.5%

Local CBD-containing suppositories are being clinically studied for postmenopausal symptoms; evidence is product-specific and not enough for broad menopause claims.

CBD has emerging pilot data; THC not preferred

UK burden: Insomnia affects around 1 in 3 people in the UK; 29% self-reported insomnia symptoms in England (2024)

CBD has strongest evidence; licensed in indication

UK burden: Approximately 4,000 to 6,300 people in the UK (using ONS mid-2025 population)

Small topical CBD studies support further investigation; evidence is limited and not established standard care.

CBD:THC combination has strongest evidence

UK burden: Over 150,000 people with MS in the UK; spasticity affects 60,000 to 120,000

CBD has emerging Phase 2 support; THC contraindicated

UK burden: Estimated 300,000+ people with opioid dependence in England; cannabis use disorder prevalence not separately UK-sourced

CBD has weak signal; non-motor symptoms only

UK burden: Around 166,000 people diagnosed with Parkinson's in the UK

CBD has emerging signal; investigational only

UK burden: England adult PTSD screen-positive prevalence: 5.7% in 2023/24

CBD has only positive evidence; THC contraindicated

UK burden: Approximately 220,000 people in the UK are currently receiving treatment for schizophrenia. Over 300,000 people in England are living with a psychotic disorder.

CBD has small acute-dose RCT support; not licensed

UK burden: Social anxiety disorder is common; precise UK prevalence estimate varies

THC analogue has limited supportive data

UK burden: More than 300,000 children and adults in the UK live with Tourette syndrome

CBD investigational (preclinical); THC unsuitable

UK burden: Approximately 1.4 million people attend A&E for head injuries annually in the UK

CBD has mechanistic and preclinical rationale in TBI, and clinical trials are underway, but human efficacy is not established.

CBD has strongest evidence; licensed in indication

UK burden: Around 3,900 people with TSC in the UK; approximately 3,300 with seizure history